๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer

โœ Scribed by Mark D. Hauge; Harry J. Long; Lynn C. Hartmann; John H. Edmonson; Maurice J. Webb; John Su

Publisher
Springer US
Year
1992
Tongue
English
Weight
192 KB
Volume
10
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Long-term intravenous hydroxyurea infusi
Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trial
โœ Martin S. Blumenreich; Michael J. Kellihan; U. Geetha Joseph; Kim A. Lalley; Eli ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 384 KB ๐Ÿ‘ 1 views

Background. Hydroxyurea is an S-phase specific drug. Constant exposure of tumor cells with a low Sphase fraction to the agent may result in improved cell kill. Because of its short half-life, a continuous intravenous infusion may result in better tumor exposure than intake by mouth. The goal of this

Phase II trial of vinblastine in advance
Phase II trial of vinblastine in advanced ovarian carcinoma
โœ Gregory P. Sutton; John A. Blessing; Mark D. Adelson; Parviz Hanjani ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› Springer US ๐ŸŒ English โš– 231 KB

A phase II trial of vinblastine in patients with refractory epithelial ovarian adenocarcinoma of the ovary was conducted by the Gynecologic Oncology Group (GOG) between March 9, 1988 and July 7, 1988. Vinblastine was administered in a dose of 9 mg/m2 intravenously every three weeks until disease pro